Skip to main content

Table 2 The number of lesions meeting each response criteria

From: Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome

Criteria

Number of lesions (%)

Diameter changes


RECIST (≥30% decrease)

4 (7%)


MASS (≥20% decrease)

9 (15%)


Choi (≥10% decrease)

13 (22%)

Density changes


MASS (≥40HU decrease or marked central necrosis)

0 (0%)


Choi (≥15% decrease)

23 (39%)

Combined diameter and density criteria


MASS (≥20% diameter decrease, ≥40HU density decrease, or marked central necrosis)

9 (15%)


Choi ((≥10% diameter decrease of ≥15% density decrease)

29 (49%)